SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) — Crinetics Prescribed drugs, Inc. (NASDAQ: ) right this moment introduced that it’ll announce its 2024 monetary outcomes after the market shut on Thursday, August 8, 2024. Second quarter monetary outcomes. The corporate’s administration will host a convention name at 4:30 p.m. ET that day to debate monetary outcomes and supply a enterprise replace.
Convention calls and webcasts
Thursday, August 8tH @ 4:30 PM ET
| home: | 1-800-267-6316 |
| Worldwide: | 1-203-518-9783 |
| Assembly ID: | CRNXQ2 |
Members can use the dial-in quantity above or name through the reside webcast within the Occasions part of the Crinetics web site. To make sure a well timed connection, members are suggested to dial in or register no less than quarter-hour earlier than the scheduled name.
This webcast will likely be archived within the Investor Relations part of www.crinetics.com.
About Crinetics Prescribed drugs, Inc.
Crinetics Prescribed drugs is a clinical-stage pharmaceutical firm centered on the invention, improvement and commercialization of novel therapies for endocrine illnesses and endocrine-related tumors. Paltusotine is an investigational, first-in-class, oral somatostatin receptor sort 2 (SST2) agonist at present in Section 3 scientific improvement for the remedy of acromegaly and Section 2 for the remedy of carcinoid syndrome related to neuroendocrine tumors. scientific improvement. Crinetics can also be growing atumelnant (CRN04894), an ongoing first-in-class oral ACTH antagonist that’s at present finishing a Section 2 scientific research for the remedy of congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All the firm’s drug candidates are orally administered small molecule novel chemical entities derived from in-house drug discovery efforts, together with further discovery applications addressing varied endocrine illnesses, resembling hyperparathyroidism, polycystic kidney illness, Grave Alzheimer’s illness, thyroid eye illness, diabetes and weight problems.
contact:
Gayatri Diwakar
Investor Relations Supervisor
gdiwakar@crinetics.com
(858)345-6340
media:
Natalie Badillo
Company Communications Government
nbadillo@crinetics.com
(858)345-6075
Supply: Crinetics Prescribed drugs, Inc.
